Proceedings of the American Thoracic Society Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Proceedings of the American Thoracic Society 6:171-179 (2009)
© 2009 The American Thoracic Society
doi: 10.1513/pats.200806-059LC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Erasmus, J. J.
Right arrow Articles by Swisher, S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Erasmus, J. J.
Right arrow Articles by Swisher, S. G.

Prognosis and Reevaluation of Lung Cancer by Positron Emission Tomography Imaging

Jeremy J. Erasmus1, Eric Rohren1 and Stephen G. Swisher2

1 Division of Diagnostic Imaging, and 2 Department of Thoracic and Cardiovascular Surgery, University of Texas M.D. Anderson Cancer Center, Houston, Texas

Correspondence and requests for reprints should be addressed to Jeremy J. Erasmus, M.D., M.D. Anderson Cancer Center, Division of Diagnostic Imaging, Unit 037, 1515 Holcombe Blvd., Houston, TX 77030. E-mail: jerasmus{at}di.mdacc.tmc.edu

ABSTRACT

Positron emission tomography (PET) imaging using 18F-2-deoxy-D-glucose, a D-glucose analog labeled with fluorine-18 (FDG-PET), is being evaluated in the assessment of prognosis and therapeutic response in patients with non–small cell lung cancer. FDG-PET imaging has the potential to allow more appropriate selection of patients for surgical resection and for neoadjuvant and aduvant chemotherapy as well as chemoradiation. Currently, the absence of standardization in how FDG-PET images are obtained and interpreted limits its widespread clinical utility. Although prospective multi-institutional trials and standardization of FDG-PET imaging protocols are required for the true utility to be determined, the evolving experience with FDG-PET imaging indicates a greater and integral role in treatment decisions. This article will discuss the assessment of prognosis and treatment response in patients with non–small cell lung cancer using FDG-PET, and will emphasize potential advantages and limitations in clinical management.

Key Words: lung cancer • PET-CT • response






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Thoracic Society. 		 
ATS 2008 State of the Art Course